Clinical trial
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With…
NCT00269854 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00269854 |
|---|---|
| Title | An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease |
| Official title | A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's Disease |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | Infliximab 5 mg/kg, Infliximab 10 mg/kg, Infliximab 20 mg/kg, Placebo |
| Enrollment | 108 |
| Start date | Jun 1, 1995 |
| Primary completion | Oct 1, 1996 |
| Completion | Oct 1, 1996 |
| First posted | Dec 26, 2005 |
| Last update posted | Nov 4, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: